Rivulet Media Inc (fka RIVU)

[Krisandtilly]

Benitec Biopharma Limited – 2014 Annual Report
Page 9
Licensed Programs
In addition to the Company’s in-house development programs, Benitec has licensed its ddRNAi technology to
four biotech companies. As each of these companies advances their clinical development their success further
validates ddRNAi.

? Breast cancer – Benitec has granted a license to Regen Biopharma for the development of a ddRNAibased
therapy called dCellVax. Regen recently announced the successful silencing of the IDO gene in
dendritic cells, an approach that in animal models has demonstrated the ability to induce regression
of breast cancer.